Orosomucoid 1 promotes colorectal cancer progression and liver metastasis by affecting PI3K/AKT pathway and inducing macrophage M2 polarization

Lei Yue, Xiaozhang Xu, Shipeng Dai, Fan Xu, Wenhu Zhao, Jian Gu, Xinzheng Dai, Xiaofeng QianScientific 2023 · DOI

Introduction

Colorectal cancer (CRC) remains a significant global health burden, with liver metastasis (CRLM) occurring in 25–30% of patients. The prognosis for CRLM is notoriously poor, often due to the lack of early predictive biomarkers and high recurrence rates post-surgery. This study identifies Orosomucoid 1 (ORM1) as a key player in driving metastatic progression through both tumor-intrinsic signaling and immune system modulation.

Identifying ORM1 via Bioinformatics

To identify potential drivers of metastasis, researchers performed a comprehensive screening of the Gene Expression Omnibus (GEO) database, focusing on datasets GSE14297, GSE49355, and GSE81558. These datasets compared primary CRC tumors with liver metastases to find genes that were consistently dysregulated during the transition to metastatic disease.

Volcano plots showing differentially expressed genes (DEGs) across three GEO datasets. Red dots indicate upregulated genes, while blue dots indicate downregulated genes.

The analysis revealed a significant number of differentially expressed genes (DEGs). By intersecting the upregulated genes across all three datasets, the researchers identified 102 common genes that were consistently elevated in metastatic tissues.

Venn diagram illustrating the overlap of upregulated genes across the three analyzed datasets, identifying 102 common candidates including ORM1.

Among these, ORM1 emerged as a top candidate, showing significant upregulation in liver metastases compared to primary tumors ($p < 0.001$).

Functional Mechanisms: Growth and Migration

ORM1 acts as a "dual-threat" oncogene. First, it directly promotes tumor cell proliferation and invasion by activating the PI3K/AKT signaling pathway, a well-known regulator of cell growth. Furthermore, ORM1 induces Epithelial-Mesenchymal Transition (EMT), characterized by the loss of the epithelial marker E-cadherin and the gain of mesenchymal markers N-cadherin and Vimentin. This molecular shift allows cancer cells to detach from the primary tumor and migrate to distant sites like the liver.

Reprogramming the Immune Microenvironment

Beyond its direct effects on tumor cells, ORM1 "reprograms" the local immune environment to favor tumor survival. The study found that ORM1 promotes the polarization of macrophages toward the M2 phenotype. Unlike M1 macrophages, which exhibit anti-tumor activity, M2 macrophages suppress the immune response and facilitate tumor growth. This shift is mediated in part by increased secretion of Interleukin-10 (IL-10). In vivo experiments demonstrated that depleting macrophages or inhibiting IL-10 partially reversed the metastatic advantage provided by ORM1.

Clinical Significance and Future Outlook

Clinical validation using patient samples confirmed that high ORM1 expression correlates with poorer disease-free survival (DFS). Notably, serum ORM1 levels were elevated in CRLM patients and decreased following surgical resection, suggesting its potential as a non-invasive biomarker for monitoring disease progression and recurrence.

While these findings are promising, further research is needed to identify the specific protein-protein interactions that trigger the PI3K/AKT pathway and to develop targeted therapies, such as monoclonal antibodies, to inhibit ORM1 activity in high-risk patients.

Summary updated

Abstract

Approximately 25-30% of those affected by colorectal cancer (CRC), the most prevalent gastrointestinal malignancy, develop metastases. The survival rate of patients with liver metastasis of CRC (CRLM) remains low owing to its unpredictability and a lack of biomarkers that can be applied to distinguish groups at higher risk for CRLM among patients with CRC. Therefore, our study aimed to find biomarkers that can predict the risk of CRLM. Screening of the Gene Expression Omnibus database, supported by an analysis of clinically obtained tissue and serum data using qPCR and ELISA, in an attempt to identify relevant biomarkers, enabled us to determine that orosomucoid 1 (ORM1) was differentially expressed in liver metastases and primary tumors of patients with CRC. Functionally, overexpression of ORM1 promoted the epithelial-mesenchymal transition and the proliferative, migratory, and invasive activities of MC38 cells and activated the PI3K/AKT signaling pathway. Moreover, MC38 cells overexpressing ORM1 enhanced the tumor immune microenvironment by promoting macrophage M2 polarization and elevating interleukin-10 (IL-10) expression. In vivo experiments further confirmed in vitro results, indicating that liver metastases elevated by ORM1 were partially attenuated by the depletion of macrophages or IL-10. Considered together, ORM1 promotes CRC progression and liver metastasis by regulating tumor cell growth and inducing macrophage M2 polarization, which mediates tumor immune tolerance, and thus acts as a potential predictive marker and therapeutic target in CRLM.
BibTeX
@inproceedings{yue2023orosomucoid,
  author = {Lei Yue and Xiaozhang Xu and Shipeng Dai and Fan Xu and Wenhu Zhao and Jian Gu and Xinzheng Dai and Xiaofeng Qian},
  title = {{Orosomucoid 1 promotes colorectal cancer progression and liver metastasis by affecting PI3K/AKT pathway and inducing macrophage M2 polarization}},
  booktitle = {Scientific},
  year = {2023},
  doi = {10.1038/s41598-023-40404-1},
}
Figure